Citation Impact
Citing Papers
Structure and Function of Leukocyte Integrins
1990
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1,which simulates an activated CD40 receptor
1998
CD34+ Cord Blood Cell-Transplanted Rag2−/− γc−/− Mice as a Model for Epstein-Barr Virus Infection
2008
Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative Disease
1989
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
Roles of the ankyrin repeats and C-terminal region of the mouse Notch1 intracellular region
1998 StandoutNobel
Antagonistic effects ofc-myc and Epstein-Barr virus latent genes on the phenotype of human B cells
2001
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
1995
Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts
1997
Global Cancer Statistics, 2002
2005 Standout
Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
1997
Epstein–Barr virus in the pathogenesis of NPC
2002
Epstein–Barr virus-associated malignancies: epidemiologic patterns and etiologic implications
2000
Deregulated c‐myc expression in epstein‐barr‐virus‐immortalized b‐cells induces altered growth properties and surface phenotype but not tumorigenicity
1990
Regulation of Interleukin-1β Transcription by Epstein–Barr Virus Involves a Number of Latent Proteins via Their Interaction with RBP
1998 StandoutNobel
Epstein-Barr virus: adaptation to a life within the immune system
1994
Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein-Barr virus and the bovine leukaemia virus
1993
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
2007 StandoutNature
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
2008 StandoutNature
Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders
2002
Delta-induced Notch Signaling Mediated by RBP-J Inhibits MyoD Expression and Myogenesis
1999 StandoutNobel
Cloning and Expression of a Murine Fascin Homolog from Mouse Brain
1995 StandoutNobel
Diagnosis of Nasopharyngeal Carcinoma by DNA Amplification of Tissue Obtained by Fine-Needle Aspiration
1992
Lysine-Independent Ubiquitination of Epstein–Barr Virus LMP2A
2002
N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2
2001
Risk factors in the development of multiple sclerosis
2007
Epstein–Barr Virus and a Cellular Signaling Pathway in Lymphomas from Immunosuppressed Patients
1998
Lethal effect of the anti-Fas antibody in mice
1993 StandoutNature
Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes
1998
Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death
1991
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data
1997
LMP1 structure and signal transduction
2001
Signal transduction by lymphocyte antigen receptors
1994 Standout
Functional Interaction between the Mouse Notch1 Intracellular Region and Histone Acetyltransferases PCAF and GCN5
2000 StandoutNobel
Latent membrane protein 1of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
1999
EBV-Infected B Cells in Infectious Mononucleosis
2000
Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins
1991 Standout
Epstein–Barr virus: 40 years on
2004 Standout
Latent membrane protein 1of Epstein-Barr virus mimics a constitutively active receptor molecule
1997
A Novel Multiple PDZ Domain-containing Molecule Interacting withN-Methyl-d-aspartateReceptors and Neuronal Cell Adhesion Proteins
1998 StandoutNobel
Transporter (TAP)‐independent processing of a multiple membrane‐spanning protein, the Epstein‐Barr virus latent membrane protein 2
1996
Head and Neck Cancer
1993 Standout
The Fas Death Factor
1995 StandoutScience
Cross-Intron Bridging Interactions in the Yeast Commitment Complex Are Conserved in Mammals
1997 StandoutNobel
LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2
1999
Tonsilar NK Cells Restrict B Cell Transformation by the Epstein-Barr Virus via IFN-γ
2008
Kaposi's Sarcoma–Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity–Based Lymphomas
1995 Standout
Immunological responses to Epstein-barr virus infection and the pathogenesis of EBV-induced diseases
1989
The epstein‐barr‐virus‐encoded membrane protein LMP but not the nuclear antigen EBNA‐1 induces rejection of transfected murine mammary carcinoma cells
1991
CD40-CD40 Ligand: A Multifunctional Receptor-Ligand Pair
1996
Degradation of the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) by the Ubiquitin-Proteasome Pathway
2000 StandoutNobel
Epstein‐barr virus‐infected b cells persist in the circulation of acyclovir‐treated virus carriers
1989
Epstein–Barr virus and oncogenesis: from latent genes to tumours
2003
Epstein–Barr virus latent membrane protein inhibits human epithelial cell differentiation
1990 Nature
Epstein-barr virus latency: LMP2, a regulator or means for Epstein- barr virus persistence?
2000
Epstein--Barr Virus Gene Expression in Nasopharyngeal Carcinoma
1988
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
1994 Standout
Co-expression of Epstein-Barr virus latent membrane protein and vimentin in “aggressive” histological subtypes of Hodgkin's disease
1993
The Tumor Suppressor Protein p16 and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring Lysine-less Proteins That Are Degraded by the Ubiquitin System
2004 StandoutNobel
TRADD–TRAF2 and TRADD–FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways
1996 Standout
Three transcriptionally distinct forms of epstein-barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage
1992
A novel form of Epstein-Barr virus latency in normal B cells in vivo
1995 Standout
RBP-Jkrepression activity is mediated by a co-repressor and antagonized by the Epstein-Barr virus transcription factor EBNA2
1995
Activation of C. elegans cell death protein CED-9 by an ammo-acid substitution in a domain conserved in Bcl-2
1994 StandoutNatureNobel
Epstein–Barr Virus Coopts Lipid Rafts to Block the Signaling and Antigen Transport Functions of the BCR
2001
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
2004 StandoutNature
The Association of Epstein-Barr Virus (Ebv) with T Cell Lymphoproliferations and hodgkin's Disease: Two New Developments in the Ebv Field
1993
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Epstein–Barr Virus Infection
2000 Standout
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1
1997 StandoutNobel
The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues
1995
The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B.
1992
The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules.
1995
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
1994 StandoutScience
Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus
1993
The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo
2002 StandoutNobel
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes
1992
Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation
1994
Identification of Virus-Encoded MicroRNAs
2004 StandoutScience
The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements.
1994
Integrins: Versatility, modulation, and signaling in cell adhesion
1992 Standout
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro
1992
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.
1993
The EBV Transforming Protein, Latent Membrane Protein 1, Mimics and Cooperates with CD40 Signaling in B Lymphocytes
1999
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
2003 StandoutNobel
Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus
1987
Down-regulation of LFA-1 Adhesion Receptors by C- myc Oncogene in Human B Lymphoblastoid Cells
1990 Science
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1
1994
Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus [see comments]
1993
HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION
1997
TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand–independent T Helper Cell Activation
1999 StandoutNobel
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
1992
Antisense to the Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 (LMP-1) Suppresses LMP-1 and Bcl-2 Expression and Promotes Apoptosis in EBV-Immortalized B Cells
1998
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation
1993
Dendritic Cells Cross-Present Latency Gene Products from Epstein-Barr Virus–Transformed B Cells and Expand Tumor-Reactive Cd8+ Killer T Cells
2001 StandoutNobel
Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein
1987
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
1985 Standout
Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1
1993
Homogeneous Glycopeptides and Glycoproteins for Biological Investigation
2002 StandoutNobel
How neuroinflammation contributes to neurodegeneration
2016 StandoutScience
Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers
1994
Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator
1995
A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2.
1992
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1
1995
NF-κB inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells
2000
Viruses in Human Cancers
1991 StandoutScienceNobel
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
2009 StandoutNobel
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
1993
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa)
1996
beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex.
1996 StandoutNobel
Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association
1991
Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype
1992
Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kilodalton actin-bundling protein
1994
Mimicry of CD40 Signals by Epstein-Barr Virus LMP1 in B Lymphocyte Responses
1999 Science
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state
1994
Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.
1996 StandoutNobel
Primary structure of the herpesvirus saimiri genome
1992
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Tolerogenic Dendritic Cells
2003 StandoutNobel
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors
1993
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide
2004
Epstein-Barr Virus LMP2A Transforms Epithelial Cells, Inhibits Cell Differentiation, and Activates Akt
2000
Epstein-Barr Virus and the Somatic Hypermutation of Immunoglobulin Genes in Burkitt's Lymphoma Cells
2001
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
1989
Transient up-regulation of P2Y2nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes
1997 StandoutNobel
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia.
1995
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa
1995
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes
1996
Role of the TRAF Binding Site and NF-κB Activation in Epstein-Barr Virus Latent Membrane Protein 1-Induced Cell Gene Expression
1998
LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha
1995
A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa
1996
Works of D Liebowitz being referenced
EVIDENCE FOR SIGNAL TRANSDUCTION THROUGH THE TNF RECEPTOR PATHWAY IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
1997
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus
1986
Two related Epstein-Barr virus membrane proteins are encoded by separate genes
1989
Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines
1989
An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes.
1987
The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts
1988
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
1990
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity
1988
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells
1992
Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin
1989